A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
About this study
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Condition
- Solid Tumors, Hematologic Malignancies
- Tested
- INCA036873
- Sponsor
- Incyte Corporation
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 16
- Minimum age: 18 years
- Study condition: Solid Tumors, Hematologic Malignancies
- Age ≥18 years.
- ECOG performance status of 0 or 1.
- Histologically confirmed:
- Clear cell renal cell carcinoma (ccRCC).
- Diffuse large B-cell lymphoma (DLBCL, NOS).
- High-grade B-cell lymphoma (HGBCL).
- Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
- Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
- Disease progression, relapse, or refractory to prior therapy:
- ccRCC: ≥1 prior line incl. ICI + TKI.
- DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
- PTCL/CTCL: ≥1 prior systemic therapy.
- Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
- Tumor tissue available for central testing.
Exclusion 9
- Untreated or progressive CNS disease unless previously treated and stable.
- Other active invasive malignancy within 2 years (except certain low-risk cancers).
- Prior CD70-targeting therapy, including CAR T.
- ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
- Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
- Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
- Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
- Pregnancy, breastfeeding, or unwillingness to use effective contraception.
- Other protocol-defined Inclusion/Exclusion Criteria may apply.
Where
22 sites, 22 recruiting
Cancer Research Sa
Adelaide, South Australia, Australia
Peter Maccallum Cancer Centre-Royal Melbourne Hospital
Melbourne, Victoria, Australia
Macquarie University Hospital
Sydney, New South Wales, Australia
Princess Alexandra Hospital Australia
Woolloongabba, Queensland, Australia
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
and 16 more sites on ClinicalTrials.gov
Contact
-
Incyte Corporation Call Center (US)
1.855.463.3463 medinfo@incyte.com
-
Incyte Corporation Call Center (ex-US)
+800 00027423 eumedinfo@incyte.com
Potential match only. Final eligibility is determined by the study team.